BC Extra | Dec 19, 2019
Company News

PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline...
BioCentury | Jul 9, 2019
Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BC Extra | Jun 3, 2019
Clinical News

June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more

Celgene highlights iberdomide data for MM at ASCO  Celgene Corp. (NASDAQ:CELG) presented data at ASCO Sunday showing that iberdomide (CC-220) plus dexamethasone led to an overall response rate (ORR) of 32%, including 17 partial responses...
BC Innovations | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BC Innovations | Feb 11, 2019
Distillery Therapeutics

Cancer

INDICATION: Melanoma In vitro , cell culture and mouse studies identified a quinazolinamine-based STK19 inhibitor that could help treat NRAS-mutant melanoma. In vitro screening of a small molecule library and optimization of the top hit yielded...
BC Week In Review | Jan 4, 2019
Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers. Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates against five oncogene targets for...
BC Extra | Jan 3, 2019
Company News

Codiak, Jazz to develop exosomes against tricky oncogenes

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers. Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates against five oncogene targets for...
BC Innovations | Nov 6, 2018
Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
BC Innovations | Sep 26, 2018
Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cell-free assays; computational models A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies. Construction of the model involves...
Items per page:
1 - 10 of 114